Antiangiogenic Nanomicelles for the Topical Delivery of Aflibercept to Treat Retinal Neovascular Disease

Bibliographische Detailangaben
Veröffentlicht in:	Advanced materials (Deerfield Beach, Fla.). - 1998. - 34(2022), 25 vom: 02. Juni, Seite e2108360
1. Verfasser:	Zhao, Xinxin (VerfasserIn)
Weitere Verfasser:	Seah, Ivan, Xue, Kun, Wong, Wendy, Tan, Queenie Shu Woon, Ma, Xiaoxiao, Lin, Qianyu, Lim, Jason Y C, Liu, Zengping, Parikh, Bhav Harshad, Mehta, Karishma N, Lai, Joel Weijia, Yang, Binxia, Tran, Kim Chi, Barathi, Veluchamy Amutha, Cheong, Kang Hao, Hunziker, Walter, Su, Xinyi, Loh, Xian Jun
Format:	Online-Aufsatz
Sprache:	English
Veröffentlicht:	2022
Zugriff auf das übergeordnete Werk:	Advanced materials (Deerfield Beach, Fla.)
Schlagworte:	Journal Article angiogenesis inhibitors drug carriers drug delivery systems micelles ophthalmic solutions retinal diseases Angiogenesis Inhibitors Recombinant Fusion Proteins Vascular Endothelial Growth Factor A mehr... aflibercept 15C2VL427D Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1

Beschreibung
Zusammenfassung:	© 2021 Wiley-VCH GmbH. The traditional intravitreal injection delivery of antivascular endothelial growth factor (anti-VEGF) to the posterior segment of the eye for treatment of retinal diseases is invasive and associated with sight-threatening complications. To avoid such complications, there has been significant interest in developing polymers for topical drug delivery to the retina. This study reports a nanomicelle drug delivery system made of a copolymer EPC (nEPCs), which is capable of delivering aflibercept to the posterior segment topically through corneal-scleral routes. EPC is composed of poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG), and polycaprolactone (PCL) segments. In this study, aflibercept-loaded nEPCs (nEPCs + A) are capable of penetrating the cornea in ex vivo porcine eye models and deliver a clinically significant amount of aflibercept to the retina in laser-induced choroidal neovascularization (CNV) murine models, causing CNV regression. nEPCs + A also demonstrate biocompatibility in vitro and in vivo. Interestingly, this study also suggests that nEPCs have intrinsic antiangiogenic properties. The ability to deliver anti-VEGF drugs and the intrinsic antiangiogenic properties of nEPCs may result in synergistic effects, which can be harnessed for effective therapeutics. nEPCs may be a promising topical anti-VEGF delivery platform for the treatment of retinal diseases
Beschreibung:	Date Completed 24.06.2022 Date Revised 24.06.2022 published: Print-Electronic Citation Status MEDLINE
ISSN:	1521-4095
DOI:	10.1002/adma.202108360